64 related articles for article (PubMed ID: 15711827)
1. Secretory transport of irinotecan metabolite SN-38 across isolated intestinal tissue.
Itagaki S; Sumi Y; Shimamoto S; Itoh T; Hirano T; Takemoto I; Iseki K
Cancer Chemother Pharmacol; 2005 May; 55(5):502-6. PubMed ID: 15711827
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic study of cancer chemotherapy].
Itoh T
Yakugaku Zasshi; 2006 Sep; 126(9):723-35. PubMed ID: 16946586
[TBL] [Abstract][Full Text] [Related]
3. Characterization of secretory intestinal transport of the lactone form of CPT-11.
Takemoto I; Itagaki S; Chiba M; Itoh T; Hirano T; Iseki K
Cancer Chemother Pharmacol; 2006 Jan; 57(1):129-33. PubMed ID: 16003561
[TBL] [Abstract][Full Text] [Related]
4. Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2.
Itoh T; Itagaki S; Sumi Y; Hirano T; Takemoto I; Iseki K
Cancer Chemother Pharmacol; 2005 May; 55(5):420-4. PubMed ID: 15565324
[TBL] [Abstract][Full Text] [Related]
5. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.
Nakatomi K; Yoshikawa M; Oka M; Ikegami Y; Hayasaka S; Sano K; Shiozawa K; Kawabata S; Soda H; Ishikawa T; Tanabe S; Kohno S
Biochem Biophys Res Commun; 2001 Nov; 288(4):827-32. PubMed ID: 11688982
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
[TBL] [Abstract][Full Text] [Related]
7. Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb/IIIa receptor antagonist, in rat small intestine.
Okudaira N; Komiya I; Sugiyama Y
J Pharmacol Exp Ther; 2000 Nov; 295(2):717-23. PubMed ID: 11046110
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of multidrug resistance-associated protein 3 (mrp3/abcc3) in the basolateral efflux of glucuronide conjugates in the mouse small intestine.
Kitamura Y; Kusuhara H; Sugiyama Y
J Pharmacol Exp Ther; 2010 Feb; 332(2):659-66. PubMed ID: 19889793
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model.
Atsumi R; Okazaki O; Hakusui H
Biol Pharm Bull; 1995 Jul; 18(7):1024-6. PubMed ID: 7581244
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of irinotecan.
Kuhn JG
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):39-42. PubMed ID: 9726089
[TBL] [Abstract][Full Text] [Related]
11. The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.
Tallman MN; Miles KK; Kessler FK; Nielsen JN; Tian X; Ritter JK; Smith PC
J Pharmacol Exp Ther; 2007 Jan; 320(1):29-37. PubMed ID: 17003228
[TBL] [Abstract][Full Text] [Related]
12. Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats.
Naruhashi K; Tamai I; Inoue N; Muraoka H; Sai Y; Suzuki N; Tsuji A
Antimicrob Agents Chemother; 2002 Feb; 46(2):344-9. PubMed ID: 11796340
[TBL] [Abstract][Full Text] [Related]
13. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes.
Shono Y; Nishihara H; Matsuda Y; Furukawa S; Okada N; Fujita T; Yamamoto A
J Pharm Sci; 2004 Apr; 93(4):877-85. PubMed ID: 14999725
[TBL] [Abstract][Full Text] [Related]
14. Biliary excretion of irinotecan and its metabolites.
Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
[TBL] [Abstract][Full Text] [Related]
15. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Iyer L; King CD; Whitington PF; Green MD; Roy SK; Tephly TR; Coffman BL; Ratain MJ
J Clin Invest; 1998 Feb; 101(4):847-54. PubMed ID: 9466980
[TBL] [Abstract][Full Text] [Related]
16. In vitro activation of irinotecan to SN-38 by human liver and intestine.
Ahmed F; Vyas V; Cornfield A; Goodin S; Ravikumar TS; Rubin EH; Gupta E
Anticancer Res; 1999; 19(3A):2067-71. PubMed ID: 10470149
[TBL] [Abstract][Full Text] [Related]
17. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.
Onoue M; Kurita A; Kado S; Matsumoto T; Kaneda N; Uchida K; Kato I; Yokokura T
Cancer Chemother Pharmacol; 2008 Apr; 61(4):595-605. PubMed ID: 17549477
[TBL] [Abstract][Full Text] [Related]
18. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
Chu XY; Kato Y; Niinuma K; Sudo KI; Hakusui H; Sugiyama Y
J Pharmacol Exp Ther; 1997 Apr; 281(1):304-14. PubMed ID: 9103511
[TBL] [Abstract][Full Text] [Related]
19. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
[TBL] [Abstract][Full Text] [Related]
20. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
